The New York firm trying to make AI something a clinician will actually sign their name to - by shipping deployed, accountable products instead of demos.
Most clinical-AI demos never reach a patient. Reveal HealthTech's whole pitch is the part that usually stalls: turning a promising model into something a hospital or pharma team runs in production.
Reveal HealthTech is an AI transformation partner for the U.S. healthcare and life sciences industries. Founded in 2023 and incubated inside two venture studios - W Health Ventures and 2070 Health - the company sells a blend of digital advisory, product engineering, and a growing set of its own AI products. Its clients range from Fortune 100 pharma companies and large hospital systems to early-stage digital health startups.
The framing the company keeps returning to is a shift "from reactive care to continuous, outcome-driven care." In practice that means cross-functional teams - clinicians, engineers, and designers in the same room - that carry a project from problem framing all the way to real-world deployment. The emphasis is less on the model's benchmark score and more on whether a clinician can trust the output enough to act on it.
That focus shows up in how Reveal talks about itself: not as another consultancy, but as a "healthcare AI specialist" sitting at the intersection of cutting-edge AI and deep clinical knowledge. It is a narrow lane, and a deliberate one.
"Make AI the most trusted and accountable partner in healthcare."
- Reveal HealthTech, stated missionThe word doing the work in that sentence is accountable. In a field where a wrong output can harm someone, accuracy on a slide is not the bar. Reveal's tagline - "precision, insight, and humanity" - puts the hardest-to-engineer quality last on purpose, and is wagering it is also the differentiator.
Reveal packages repeatable AI work into named products, backed by advisory and engineering teams that customize and deploy them.
A multimodal AI platform that uncovers hidden eligibility signals across imaging, labs, and physician notes - accelerating recruitment, reducing screen failures, and turning weeks of manual chart review into a real-time adaptive workflow.
A platform for rapidly building intelligent agents that unify unstructured information - clinical notes to diagnostic images - into actionable insight that improves decisions and speeds up operations.
Intelligently matches patients and practitioners by balancing preferences, availability, and drive times - making scheduling smoother, more efficient, and more personal.
A prototyping and research hub for generative AI applications and healthcare research partnerships, spanning biomarker modeling, scheduling optimization, and more.
Six core capabilities - AI acceleration, strategic advisory, organizational enablement, product engineering, platform development, and design - delivered by cross-functional, clinically grounded teams.
Cloud-native, HIPAA-compliant delivery backed by AWS Advanced Tier Partner status - the plumbing that lets health systems put these tools into production.
A young firm that moved quickly from incubation to an institutional round.
The clearest proof point Reveal cites: it helped a $40B U.S. medical device company improve patient adherence through AI-driven data integration, then packaged the work as a reusable blueprint for other clients. That "build once, reuse" instinct is how a services firm turns one-off wins into a product line.
Reveal competes against in-house health-system teams, generalist IT consultancies, and point-solution AI vendors. Its wedge is specialization plus deployment.
Clinical depth in the room, not on retainer - teams pair engineers with medical expertise.
Deployment over demos - the deliverable is a shipped, accountable workflow.
Reusable blueprints - engagements compound into products instead of repeating.
HIPAA + AWS Advanced Tier - built for production in regulated environments.
A generalist consultancy can write the strategy deck; a point vendor can ship one feature. Reveal's bet is that healthcare buyers increasingly want a partner that understands the clinic and can put working software in front of a doctor - and will pay for the narrow specialist over the broad one.
Sanchit Mullick, Dr. Salim Afshar, and Andrew Bravo launch Reveal, incubated by W Health Ventures and 2070 Health.
Stands up its prototyping lab and delivers advisory and product-engineering engagements.
BioCanvas, Prism AI, and CareIQ take shape as flagship products.
Leo Capital leads, with Sanos Capital participating.
The wider team blends alumni of MIT, Harvard Medical, and UC Berkeley with operators from Boston Children's, Mass General, SpaceX, NASA, Athena Health, and Infosys - split across a New York leadership base and a large Bengaluru engineering team.
Reveal's Series A drew coverage as it pushes AI deeper into U.S. healthcare.